Genome-wide Association Study Identifies Common Variants at Four Loci As Genetic Risk Factors for Parkinson's Disease

Overview

Journal Nat Genet

Specialty Genetics

Date 2009 Nov 17

PMID 19915576

Citations 675

Authors

Wataru Satake

Yuko Nakabayashi

Ikuko Mizuta

Yushi Hirota

Chiyomi Ito

Michiaki Kubo

Takahisa Kawaguchi

Tatsuhiko Tsunoda

Masahiko Watanabe

Atsushi Takeda

Hiroyuki Tomiyama

Kenji Nakashima

Kazuko Hasegawa

Fumiya Obata

Takeo Yoshikawa

Hideshi Kawakami

Saburo Sakoda

Mitsutoshi Yamamoto

Nobutaka Hattori

Miho Murata

Yusuke Nakamura

Tatsushi Toda

Affiliations

Soon will be listed here.

Abstract

To identify susceptibility variants for Parkinson's disease (PD), we performed a genome-wide association study (GWAS) and two replication studies in a total of 2,011 cases and 18,381 controls from Japan. We identified a new susceptibility locus on 1q32 (P = 1.52 x 10(-12)) and designated this as PARK16, and we also identified BST1 on 4p15 as a second new risk locus (P = 3.94 x 10(-9)). We also detected strong associations at SNCA on 4q22 (P = 7.35 x 10(-17)) and LRRK2 on 12q12 (P = 2.72 x 10(-8)), both of which are implicated in autosomal dominant forms of parkinsonism. By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for PD and BST1 and MAPT as loci showing population differences. Our results identify two new PD susceptibility loci, show involvement of autosomal dominant parkinsonism loci in typical PD and suggest that population differences contribute to genetic heterogeneity in PD.

Citing Articles

IL-6 Does Not Influence the Expression of and Other Mg-Homeostatic Factors.

Brodnanova M, Cibulka M, Grendar M, Gondas E, Kolisek M Int J Mol Sci. 2025; 25(24.

PMID: 39769039 PMC: 11675721. DOI: 10.3390/ijms252413274.

Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells.

Kolotyeva N, Groshkov A, Rozanova N, Berdnikov A, Novikova S, Komleva Y Biomolecules. 2025; 14(12.

PMID: 39766263 PMC: 11673498. DOI: 10.3390/biom14121556.

TFE3-mediated neuroprotection: Clearance of aggregated α-synuclein and accumulated mitochondria in the AAV-α-synuclein model of Parkinson's disease.

He X, Chen M, Fan Y, Wu B, Dong Z Genes Dis. 2025; 12(2):101429.

PMID: 39759118 PMC: 11697191. DOI: 10.1016/j.gendis.2024.101429.

Exome sequencing in Asian populations identifies low-frequency and rare coding variation influencing Parkinson's disease risk.

Chew E, Liu Z, Li Z, Chung S, Lian M, Tandiono M Nat Aging. 2024; 5(2):205-218.

PMID: 39572736 PMC: 11839463. DOI: 10.1038/s43587-024-00760-7.

Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2.

Raig N, Surridge K, Sanz-Murillo M, Dederer V, Kramer A, Schwalm M bioRxiv. 2024; .

PMID: 39554022 PMC: 11565912. DOI: 10.1101/2024.09.17.613365.

References

Webb A, Miller B, Bonasera S, Boxer A, Karydas A, Wilhelmsen K . Role of the tau gene region chromosome inversion in progressive supranuclear palsy, corticobasal degeneration, and related disorders. Arch Neurol. 2008; 65(11):1473-8. PMC: 2680206. DOI: 10.1001/archneur.65.11.1473. View

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

Biskup S, Mueller J, Sharma M, Lichtner P, Zimprich A, Berg D . Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann Neurol. 2005; 58(6):905-8. DOI: 10.1002/ana.20664. View

Lee H . Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol. 2001; 41:317-45. DOI: 10.1146/annurev.pharmtox.41.1.317. View

Thomas B, Beal M . Parkinson's disease. Hum Mol Genet. 2007; 16 Spec No. 2:R183-94. DOI: 10.1093/hmg/ddm159. View

. A haplotype map of the human genome. Nature. 2005; 437(7063):1299-320. PMC: 1880871. DOI: 10.1038/nature04226. View

Warner T, Schapira A . Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S16-23; discussion S23-5. DOI: 10.1002/ana.10487. View

. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447(7145):661-78. PMC: 2719288. DOI: 10.1038/nature05911. View

West A, Moore D, Biskup S, Bugayenko A, Smith W, Ross C . Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005; 102(46):16842-7. PMC: 1283829. DOI: 10.1073/pnas.0507360102. View

10.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

11.

Hutton M, Lendon C, Rizzu P, Baker M, Froelich S, Houlden H . Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998; 393(6686):702-5. DOI: 10.1038/31508. View

12.

Pittman A, Myers A, Abou-Sleiman P, Fung H, Kaleem M, Marlowe L . Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005; 42(11):837-46. PMC: 1735957. DOI: 10.1136/jmg.2005.031377. View

13.

Wilson C, Callaway J . Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol. 2000; 83(5):3084-100. DOI: 10.1152/jn.2000.83.5.3084. View

14.

Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y . Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet. 2006; 15(7):1151-8. DOI: 10.1093/hmg/ddl030. View

15.

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

16.

ostvold A, Norum J, Mathiesen S, Wanvik B, Sefland I, Grundt K . Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem. 2001; 268(8):2430-40. DOI: 10.1046/j.1432-1327.2001.02120.x. View

17.

Kolisek M, Launay P, Beck A, Sponder G, Serafini N, Brenkus M . SLC41A1 is a novel mammalian Mg2+ carrier. J Biol Chem. 2008; 283(23):16235-47. PMC: 2414286. DOI: 10.1074/jbc.M707276200. View

18.

Garruto R, Yanagihara R, Gajdusek D . Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology. 1985; 35(2):193-8. DOI: 10.1212/wnl.35.2.193. View

19.

Uldry M, Ibberson M, Horisberger J, Chatton J, Riederer B, Thorens B . Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 2001; 20(16):4467-77. PMC: 125574. DOI: 10.1093/emboj/20.16.4467. View

20.

Farrer M . Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006; 7(4):306-18. DOI: 10.1038/nrg1831. View